Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.
Several studies show that calcium-binding protein S100B is increased in schizophrenia and may be involved in the pathogenesis of tardive dyskinesia (TD). We therefore compared serum S100B levels in normal controls (n=60), schizophrenic patients with (n=32) and without TD (n=50). Assessments included the abnormal involuntary movement scale (AIMS) and the positive and negative syndrome scale (PANSS). Serum S100B levels were measured by enzyme-linked immunosorbent assay (ELISA). The results indicated that patients with TD had higher serum S100B levels than normals and those without TD. Serum S100B levels were positively correlated with AIMS scores in patients with TD. These data suggest that increased S100B levels may be related to neuro-degeneration, associated with TD pathophysiology.
Zhang
Xiang Yang
XY
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA. xyzhang@bcm.edu
Xiu
Mei Hong
MH
Chen
Da Chun
DC
Zhu
Feng Yan
FY
Wu
Gui Ying
GY
Haile
Colin N
CN
Lu
Lin
L
Kosten
Therese A
TA
Kosten
Thomas R
TR
D000328:Adult; D017109:Akathisia, Drug-Induced / Q000097:blood* / Q000150:complications*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000097:blood*; D012044:Regression Analysis; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood*; D012559:Schizophrenia / Q000097:blood* / Q000150:complications*; D012720:Severity of Illness Index
D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; C579160:S100B protein, human